

BURCON RAISES \$630,000 FROM WARRANT EXERCISES

Vancouver, British Columbia, February 27, 2007 – Burcon NutraScience Corporation (TSX-V: BU) announces today that it has received a total of \$630,131 from the exercise of share purchase warrants.

Warrants to acquire a total of 273,970 common shares were exercised. The warrants were originally issued in August 2006 in conjunction with a rights offering of Burcon's shares. The warrants would have expired on February 28, 2007. After the issuance of the shares relating to the exercise of these warrants, Burcon has 24,514,801 common shares issued and outstanding.

On December 31, 2006 - the most recent balance sheet date – the Company's cash position amounted to \$5,656,061. Burcon management estimates that, with the addition of the \$630,131 received from the exercise of these warrants, it has sufficient cash on hand to fund its expected level of operations and working capital requirements through October, 2009. This estimate excludes potential proceeds from any outstanding stock options that may be exercised.

“Burcon is pleased with this demonstration of continued support from its shareholders,” stated Johann F. Tergesen, Burcon's President & COO who added, “We are now even better positioned to continue through the next stages of our development plan and the commercialization of Puratein® and Supertein™.”

Burcon also provides the following update of activities:

During the past three quarters, Burcon has focused its work on the large-scale production of Puratein® and Supertein™. Large quantities of both proteins are needed in order to provide Archer Daniels Midland's (“ADM”) customers with samples for applications testing. Burcon previously announced that it had entered into a number of three way material transfer agreements (“MTAs”) among Burcon, ADM and certain major food and beverage companies as well as a large multi-national pharmaceutical company.

The MTAs enable ADM to provide samples of Burcon's proteins to these companies to test in food matrices, beverages and nutritional products etc., while protecting certain rights and intellectual property interests of all of the parties involved. The rights defined in the MTAs include intellectual property issues, confidentiality terms and matters governing the publication of findings. These third-party applications tests precede the toxicology trials but ultimately form part of the regulatory recognition process in that they help to establish the probable commercial uses for Burcon's proteins.

During the past year, Burcon also announced that it has been granted a number of U.S. patents over commercially important protein extraction and purification technologies as well as over the functional uses of Puratein® and Supertein™ blends in food and beverage products. Burcon now holds five U.S. patents over canola protein processing technology

and canola protein isolate product uses. Additionally, Burcon has filed nineteen more patent applications. The nineteen patent applications, currently being reviewed by the United States Patent and Trademark Office can be grouped into three categories: applications to protect additional novel protein extraction and purification technologies; applications to protect the uses of Puratein® and Supertein™ for example as functional food and beverage ingredients; and applications to protect the “signature characteristics” of Puratein® and Supertein™.

About Burcon NutraScience

Burcon is a research and development company developing a portfolio of composition, application, and process patents around its plant protein extraction and purification technology. The goal of Burcon’s research is to develop its patented process to utilize inexpensive oilseed meals for the production of purified plant proteins that exhibit valuable nutritional, functional or nutraceutical profiles. Burcon, in conjunction with Archer Daniels Midland, is currently focusing its efforts on developing the world's first commercial canola proteins, Puratein® and Supertein™. Canola, recognized for its nutritional qualities, is the second-largest oilseed crop in the world after soybeans. Burcon’s goal is to develop Puratein and Supertein to participate with soy, dairy, and egg proteins in the expanding multi-billion-dollar protein ingredient market, with potential uses in prepared foods, nutritional supplements, and personal care products.

###

ON BEHALF OF THE BOARD OF DIRECTORS

“Johann F. Tergesen”

Johann F. Tergesen

President & Chief Operating Officer

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy of the content of the information contained herein. This press release contains forward-looking statements that involve risks and uncertainties. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our products ,statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact. Our expectations regarding the prospect for future success depend upon our ability to develop and sell products, which we do not produce today and cannot be sold without further research and development. When used in this press release, the words “goal,”“intend,” “believes” and “potential” and similar expressions,,generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties. In light of the many risks and uncertainties surrounding the development of a source of protein from canola meal, you should understand that we cannot assure you that the forward looking statements contained in this press release will be realized.

For more information, please contact:

Jade Cheng, Chief Financial Officer
Burcon NutraScience Corporation
(604) 733-0896 / (888) 408-7960 toll-free
jcheng@burcon.ca www.burcon.ca

AXINO AG

Sven Olsson, Investor Relations Europe
Silberburgstraße 112, D-70176 Stuttgart, Germany
Tel. +49-711-25 35 92-30 / Fax +49-711-25 35 92-33
olsson@axino.de www.burcon.net

London, UK

Archie Adams, Corporate Development

Burcon NutraScience Corporation

M. +44 (0) 7768 774311

T. +44 (0) 1235 524959

archie.adams@burcon.ca